Drug Combination Details
| General Information of the Combination (ID: C80534) | |||||
|---|---|---|---|---|---|
| Name | Chlorogenic acid NP Info | + | Regorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | PSMC4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | TSC2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TSC2 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | PLC/PRF/5 | CVCL_0485 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Chlorogenic acid improves the regorafenib effects in human hepatocellular carcinoma cells. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PLC/PRF/5 | CVCL_0485 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells. Int J Mol Sci. 2018 May 19;19(5):1518. | |||
